Charles W. Flexner, M.D.


Descriptive text is not available for this image

  • Professor of Medicine, Divisions of Clinical Pharmacology and Infectious Diseases, Johns Hopkins University School of Medicine
  • Professor of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine
  • Professor of International Health, Johns Hopkins Bloomberg School of Public Health
  • Director, Johns Hopkins AIDS Clinical Trials Unit
  • Director, Outpatient General Clinical Research Center, Johns Hopkins University
  • Associate Program Director, Johns Hopkins Institute for Clinical and Translational Research


  • 66 peer-reviewed research publications
  • 89 chapters, review articles, and letters
  • Co-author, with Paul Pham, of Antiretroviral Drug Interactions: A Practical Approach
  • Author of Protease Inhibitors in AIDS Therapy


  • M.D., Johns Hopkins University School of Medicine
  • Residency in Internal Medicine, Stanford University Medical Center
  • Medical Staff Fellowship, NIAID, NIH, Bethesda, MD
  • Fellowship in Infectious Diseases and Clinical Pharmacology, Johns Hopkins University School of Medicine


  • American Society for Clinical Pharmacology and Therapeutics
  • International Society for Antiviral Research
  • American Federation for Medical Research (President-Elect)
  • International AIDS Society
  • American Society for Microbiology
  • Association of Specialty Professors
  • Board of Directors, Association for Patient-Oriented Research

Editorial Boards

  • Associate Editor, AIDS Research and Human Retroviruses
  • Antiviral Research
  • Clinical Pharmacology and Therapeutics
  • Clinical and Translational Science
  • Faculty of 1000 Biology
  • Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
  • Journal of Infectious Diseases Medicine
  • Journal of Investigative Medicine
  • Reviews in Antiviral Therapy


  • Principal Investigator: AIDS Clinical Trials Group (ACTG)


  • Research Support Boehringer-Ingelheim, GlaxoSmithKline, Tibotec
  • Advisory Board Bristol Myers-Squibb, Merck, Tibotec, Vertex
  • ConsultantAGI Therapeutics, Genzyme Corporation, Inhibitex, Schering-Plough
  • Honoraria Abbott Laboratories

Last updated: January 21, 2014